Aldeyra Therapeutics (ALDX) Competitors $2.78 -0.15 (-5.12%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.83 +0.05 (+1.80%) As of 06/13/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. BCAX, EOLS, PHAT, CAPR, STOK, UPB, BCYC, DNTH, KURA, and MRVIShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Bicara Therapeutics (BCAX), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), Capricor Therapeutics (CAPR), Stoke Therapeutics (STOK), Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Dianthus Therapeutics (DNTH), Kura Oncology (KURA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry. Aldeyra Therapeutics vs. Its Competitors Bicara Therapeutics Evolus Phathom Pharmaceuticals Capricor Therapeutics Stoke Therapeutics Upstream Bio Bicycle Therapeutics Dianthus Therapeutics Kura Oncology Maravai LifeSciences Aldeyra Therapeutics (NASDAQ:ALDX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Does the media prefer ALDX or BCAX? In the previous week, Bicara Therapeutics had 10 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 11 mentions for Bicara Therapeutics and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.82 beat Bicara Therapeutics' score of 0.74 indicating that Aldeyra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aldeyra Therapeutics Very Positive Bicara Therapeutics Positive Does the MarketBeat Community believe in ALDX or BCAX? Aldeyra Therapeutics received 470 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Bicara Therapeutics an outperform vote while only 69.33% of users gave Aldeyra Therapeutics an outperform vote. CompanyUnderperformOutperformAldeyra TherapeuticsOutperform Votes48669.33% Underperform Votes21530.67% Bicara TherapeuticsOutperform Votes1672.73% Underperform Votes627.27% Is ALDX or BCAX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aldeyra TherapeuticsN/A -43.01% -33.62% Bicara Therapeutics N/A N/A N/A Which has higher valuation and earnings, ALDX or BCAX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAldeyra TherapeuticsN/AN/A-$37.54M-$0.97-2.87Bicara TherapeuticsN/AN/AN/AN/AN/A Do analysts recommend ALDX or BCAX? Aldeyra Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 241.73%. Bicara Therapeutics has a consensus target price of $31.86, suggesting a potential upside of 193.90%. Given Aldeyra Therapeutics' higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ALDX or BCAX? 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 15.5% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBicara Therapeutics beats Aldeyra Therapeutics on 7 of the 11 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.51M$6.88B$5.58B$8.51BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-2.878.5026.7819.64Price / SalesN/A263.12404.49152.18Price / CashN/A65.8538.2534.64Price / Book1.366.536.964.59Net Income-$37.54M$143.48M$3.23B$248.23M7 Day Performance4.51%-0.19%-1.23%-1.06%1 Month Performance28.11%11.65%8.34%3.36%1 Year Performance-25.47%3.22%33.30%13.78% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics2.8512 of 5 stars$2.78-5.1%$9.50+241.7%-28.0%$166.51MN/A-2.8715Positive NewsGap DownBCAXBicara Therapeutics2.0603 of 5 stars$11.48-0.2%$31.86+177.5%N/A$626.07MN/A0.0032Analyst RevisionEOLSEvolus4.0569 of 5 stars$9.65-3.9%$23.75+146.1%-14.3%$622.19M$275.46M-10.60170Insider TradeHigh Trading VolumePHATPhathom Pharmaceuticals3.9526 of 5 stars$8.83-1.0%$17.50+98.2%-2.8%$616.46M$81.86M-1.55110Gap DownHigh Trading VolumeCAPRCapricor Therapeutics2.2536 of 5 stars$13.38-6.0%$35.50+165.3%+122.7%$611.16M$17.36M-12.62N/AAnalyst ForecastOptions VolumeAnalyst RevisionGap DownSTOKStoke Therapeutics3.6046 of 5 stars$11.13-0.1%$23.20+108.4%-34.2%$607.67M$190.91M-5.30100Analyst RevisionUPBUpstream Bio1.751 of 5 stars$11.29+0.2%$56.50+400.4%N/A$607.33M$2.30M0.0038Gap DownBCYCBicycle Therapeutics3.3459 of 5 stars$8.54-0.1%$25.00+192.7%-65.6%$591.43M$25.72M-2.60240News CoverageAnalyst RevisionDNTHDianthus Therapeutics1.3767 of 5 stars$18.19-3.5%$53.00+191.4%-32.1%$584.99M$6.52M-7.2880Analyst RevisionKURAKura Oncology4.3526 of 5 stars$6.73flat$24.50+264.0%-70.1%$582.65M$67.99M-2.85130Analyst RevisionMRVIMaravai LifeSciences4.0204 of 5 stars$2.28-4.6%$6.64+191.2%-72.6%$580.63M$241.86M-1.39610Options VolumeGap Down Related Companies and Tools Related Companies BCAX Competitors EOLS Competitors PHAT Competitors CAPR Competitors STOK Competitors UPB Competitors BCYC Competitors DNTH Competitors KURA Competitors MRVI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
